Emmaus Life Sciences, Inc.
No SEC Form 4 filings for $EMMA in the last 30 days.
See all $EMMA insider activity →Emmaus Life Sciences, Inc. (EMMA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ea030209901ex99-1.htm PRESS RELEASE DATED AUGUST 14, 2026 Exhibit 99.1 Emmaus Life Sciences Reports Quarterly Financial Results Torrance CA, August 14, 2026 - Emmaus Life Sciences, Inc. (OTCQB: EMMA) , a commercial-stage biopharmaceutical company and leader in the treat
Over the past 7 days, alphai's AI scored 1 news story mentioning EMMA (Emmaus Life Sciences, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Revenue and operating income improved materially due to upfront license revenue recognition, while cash remains modest.
alphai scores every news story that mentions EMMA with an AI model for sentiment and relevance, and aggregates insider trades from Emmaus Life Sciences, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Emmaus Life Sciences, Inc. (EMMA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ea030209901ex99-1.htm PRESS RELEASE DATED AUGUST 14, 2026 Exhibit 99.1 Emmaus Life Sciences Reports Quarterly Financial Results Torrance CA, August 14, 2026 - Emmaus Life Sciences, Inc. (OTCQB: EMMA) , a commercial-stage biopharmaceutical company and leader in the treat
6 min read